Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Omeros

4 Biotech Stocks Lifting Off As Momentum Builds

Biotech stocks have trailed the broader market this year, but more names are starting to show strength as the rally expands and major indexes reach record levels. Here's a look at four stocks showing notable momentum gains.

Hims & Hers, Salesforce, Omeros, United Airlines, And Sea Ltd: Why These 5 Stocks Are On Investors' Radars Today

Hims & Hers, Salesforce, Omeros, United Airlines, And Sea Ltd: Why These 5 Stocks Are On Investors' Radars Today

Major U.S. indices ended mixed on Wednesday, with the Dow Jones Industrial Average slipping 0.04% to 46,253.31. The SP 500 added 0.4% to 6,671.06, while the Nasdaq climbed nearly 0.7% to 22,670.08.These are the top stocks that gained the attention of retail traders and investors through the day: Hims Hers…

Omeros Stock Skyrockets After Novo Nordisk Strikes $2.1B Rare Disease Drug Deal

Omeros Stock Skyrockets After Novo Nordisk Strikes $2.1B Rare Disease Drug Deal

Biotech breakthroughs are reshaping the pharmaceutical landscape, sparking lucrative deals and redefining the future of rare disease treatment. Omeros Corporation (NASDAQ:OMER) stock is rallying on Wednesday, with a session volume of 89.21 million versus the average volume of 1.11 million, as per data from Benzinga Pro.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary

Pfizer (NYSE:PFE) announced positive top-line results from the pivotal Phase 3 trial assessing the safety, tolerability, and immunogenicity of its investigational pentavalent meningococcal vaccine (MenABCWY) in healthy individuals 10 through 25 years of age. The trial met all primary and secondary endpoints. Pfizer shares traded in a range of $45.7…

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has approved Bluebird bio’s (NASDAQ:BLUE) lead asset ZYNTEGLO (betibeglogene autotemcel) to treat the underlying genetic cause of beta‑thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions. Bluebird shares traded in a range of $6.13 to $8.18 on a day…

Recap Of Friday's Biotech Catalysts - End of The Day Summary

The U.S. Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ (NASDAQ:ARQT) New Drug Application (NDA) for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis in patients 12 years of age or older. The company expects commercial launch of the product in Mid-August. Arcutis shares traded in a range of…

Benzinga's Top Ratings Upgrades, Downgrades For June 8, 2022

inkl

Read news from The Economist, FT, and more,
with one subscription

Omeros: Q1 Earnings Insights

Omeros: Q1 Earnings Insights

Omeros (NASDAQ:OMER) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Omeros beat estimated earnings by 25.35%, reporting an EPS of $-0.53 versus an estimate of $-0.71.

Omeros Earnings Preview

Omeros Earnings Preview

Omeros (NASDAQ:OMER) is set to give its latest quarterly earnings report on Tuesday, 2022-05-10. Here's what investors need to know before the announcement. Analysts estimate that Omeros will report an earnings per share (EPS) of $-0.71.

Omeros's Return On Capital Employed Insights

Omeros's Return On Capital Employed Insights

According to Benzinga Pro, during Q4, Omeros (NASDAQ:OMER) earned $280.62 million, a 1336.05% increase from the preceding quarter. Omeros also posted a total of $30.84 million in sales, a 2.8% increase since Q3.

Omeros: Q4 Earnings Insights

Omeros: Q4 Earnings Insights

Omeros (NASDAQ:OMER) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Omeros missed estimated earnings by 2.78%, reporting an EPS of $-0.37 versus an estimate of $-0.36.

Omeros Submits Response To FDA Regarding Narsoplimab Application In HSCT-TMA

Omeros Submits Response To FDA Regarding Narsoplimab Application In HSCT-TMA

Omeros Corporation (NASDAQ: OMER) has submitted to the FDA its response to Complete Response Letter for narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA).

1

People

Shivdeep Dhaliwal

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

European Commission

United Airlines

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Dow Jones Industrial Average

Places

367,194 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play